Insomnia News and Research

Latest Insomnia News and Research

HCMS, ACOEM announce important expansion to Blueprint for Health

The American College of Occupational and Environmental Medicine (ACOEM) and the HCMS Group have announced an important expansion to their "Blueprint for Health" - a free internet-based calculating tool that helps employers better comprehend and analyze the impact of medical costs, absence, and work impairment among their employees.

5 Jun 2012

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.

2 Jun 2012

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

CHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington's disease (HD). Currently, no treatment exists to slow or halt the progression of HD, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.

21 May 2012

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.

18 May 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

Caffeine consumption: How much is too much?

Chocolate, coffee and cola are perhaps three of your favourite consumables; however, they are also three caffeine-rich substances which all contribute to your daily caffeine consumption. According to the BBC, people should not exceed 400mg caffeine a day, and this limit halves for pregnant women, for which only 200mg/day is recommended.

10 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Antidepressives reduce risk of suicides in schizophrenic patients

Antidepressive drugs reduce the mortality rate of schizophrenic patients, while treatment with bensodiazepines greatly increases it, especially as regards suicide. Giving several antipsychotics simultaneously, however, seems to have no effect at all. This according to a new study examining different drug combinations administered to patients with schizophrenia.

9 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Antibiotic effective for plague gets FDA nod

Federal regulators – The Food and Drugs Administration (FDA), have approved use of an antibiotic to treat plague, an extremely rare, sometimes-fatal bacterial infection.

30 Apr 2012

FDA approves Levaquin for plague

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.

30 Apr 2012

Study reveals direct correlation between negative thinking about pain and poor sleep

Chronic pain sufferers who learn to dwell less on their ailments may sleep better and experience less day-to-day pain, according to results of research conducted on 214 people with chronic face and jaw pain.

27 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

Change in attitude may ease chronic pain by aiding sleep: Study

26 Apr 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Researchers develop Bergen Work Addiction Scale

Researchers from Norway and the United Kingdom have developed a new instrument to measure work addiction: The Bergen Work Addiction Scale. The new instrument is based on core elements of addiction that are recognised as diagnostic criteria for several addictions.

24 Apr 2012

Poor sleep not a significant predictor of fibromyalgia pain intensity

Patients coping with the complex pain disorder fibromyalgia often have difficulty sleeping, and a new study published in The Journal of Pain reports that despite the negative quality of life implications, poor sleep is not a significant predictor of fibromyalgia pain intensity and duration.

23 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

Insomnia News and Research

Latest Insomnia News and Research

HCMS, ACOEM announce important expansion to Blueprint for Health

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Caffeine consumption: How much is too much?

Sunovion announces results from LATUDA open-label study for schizophrenia

Antidepressives reduce risk of suicides in schizophrenic patients

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Antibiotic effective for plague gets FDA nod

FDA approves Levaquin for plague

Study reveals direct correlation between negative thinking about pain and poor sleep

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Change in attitude may ease chronic pain by aiding sleep: Study

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Researchers develop Bergen Work Addiction Scale

Poor sleep not a significant predictor of fibromyalgia pain intensity

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Insomnia News and Research

Latest Insomnia News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in